Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790277 | Urologic Oncology: Seminars and Original Investigations | 2017 | 8 Pages |
Abstract
CTCs were present in 19% of patients with advanced urothelial tumors and were associated with metastatic disease on FDG-PET-CT and with increased risk of disease progression after RC. A significant portion of urothelial cancer cells do express EpCAM and can thus be identified using EpCAM-antigen-based CTC detection methods.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Johan M.D., Kristina Ph.D., Helgi M.D., Fredrik M.D., Ph.D., Oliver M.D., Ph.D., Lisa M.D., Ph.D., Gottfrid Ph.D., Sigurdur M.D., Ph.D.,